Cyrus Biotechnology, Inc.
Engineered uricase enzyme variants for gout treatment with reduced immunogenicity and improved thermostability
- Sector
- Biotech
- Headquarters
- WA
- Founded
- 2014
- Latest Form D
- $1.1M, Jul 2025
- Total capital
- $29.1M
- Federal grants
- $984K
- 4 awards · 2016–2024
- Rank in peer group#315 of 326
- Private capital raised
- $28.2M
- 10 Form D · last Jul 2025
- 15 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 11 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 10th filing$1.1M
- Private capital raisedForm D · SEC · 9th filing$3.2M
- Federal grantHealth and Human S · Phase I · Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases$300K
- Federal grantHealth and Human S · Phase I · Advanced Uricase Engineering for Improved Outcomes in Gout Patients$299K
- Private capital raisedForm D · SEC · 8th filing$2.7M
- Federal grantHealth and Human S · Phase I · Optimization of a broad and potent decoy receptor for SARS-associated viruses$161K
- Private capital raisedForm D · SEC · 7th filing$9.1M
- Private capital raisedForm D · SEC · 6th filing$1.1M
- Private capital raisedForm D · SEC · 5th filing$8M
- Private capital raisedForm D · SEC · 4th filing$1M
- Private capital raisedForm D · SEC · 3rd filing$490K
- Private capital raisedForm D · SEC · 2nd filing$535K
- Private capital raisedForm D · SEC · 1st filing$850K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · An easy-to-use and powerful tool for improved Rosetta comparative modeling of proteins$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Yifan SongResearcherExecutive Officer, Director, PromoterLinked by $225K in grants as PI
- Anthony ManningDirectorNamed in SEC Form D filings
- Chad WaiteDirectorNamed in SEC Form D filings
- Eric BellDirectorNamed in SEC Form D filings
- Gus TaiDirectorNamed in SEC Form D filings
- Jason SmithDirectorNamed in SEC Form D filings
Show all 11 people
- Javier CastellanosExecutive Officer, DirectorNamed in SEC Form D filings
- Lucas NivonExecutive Officer, DirectorNamed in SEC Form D filings
- Mark BenjaminExecutive OfficerNamed in SEC Form D filings
- Nivon LucasExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Ramakrishna SatyavoluDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 11- PendingEngineered Type II Cas Polynucleotides With Reduced Immunogenicity And Uses ThereofUSPTOApplication 19348206
- PendingEngineered Receptors And Monoclonal Antibodies For Coronavirus And Uses ThereofUSPTOApplication 18691187
- PendingIdes Variant Proteins And Methods Of Using The SameUSPTOApplication 63699603
Show all 11 patent records
- Engineered Type II Cas Polynucleotides With Reduced Immunogenicity And Uses ThereofJan 29, 2026 · Application 19348206Pending
- Engineered Receptors And Monoclonal Antibodies For Coronavirus And Uses ThereofDec 5, 2024 · Application 18691187Pending
- Ides Variant Proteins And Methods Of Using The SameApplication 63699603Pending
- Ides Variant Proteins And Methods Of Using The SameApplication PCTUS2024022411Pending
- Soluble Angiotensin-converting Enzyme 2 (ACE2) Proteins And ACE2 Fusion ProteinsApplication PCTUS2023082361Pending
- Engineered Type II Cas Polynucleotides With Reducedimmunogenicity And Uses ThereofApplication 63493931Pending
- Engineered Type V Cas Polynucleotides With Reduced Immunogenicity And Uses ThereofApplication 63493942Pending
- Soluble Angiotensin-converting Enzyme 2 (ACE2) Proteins And ACE2 Fusion ProteinsApplication 63483911Pending
- Soluble Angiotensin-converting Enzyme 2 (ACE2) Proteins And ACE2 Fusion ProteinsApplication 63386075Pending
- Soluble Angiotensin-converting Enzyme 2 (ACE2) Proteins And ACE2 Fusion ProteinsApplication 19136134Pending
- Ides Variant Proteins And Methods Of Using The SameApplication PCTUS2025048171Pending
Related companies, and why
- Biomea Fusion, Inc.Similar federal contract value in Biotech · null in contracts
- Azitra Inc.Similar federal contract value in Biotech · null in contracts
- Molecular Assemblies, Inc.Similar federal contract value in Biotech · null in contracts
- POLARITYTE, INC.Similar federal contract value in Biotech · null in contracts
- Grace Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- VISTERRA, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .